Clinical Pharmacokinetics

, Volume 21, Issue 3, pp 155–164 | Cite as

Liposomal Drug Delivery

Advantages and Limitations from a Clinical Pharmacokinetic and Therapeutic Perspective
  • Robert M. Fielding
Leading Article

Keywords

Sodium Cromoglycate Liposomal Amphotericin Prolonged Release AmBisome Cholesterol Sulfate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abra RM, Hunt CA, Lau DT. Liposome disposition in vivo: VI. delivery to the lung. Journal of Pharmaceutical Sciences 73: 203–206, 1984PubMedCrossRefGoogle Scholar
  2. Ahmad I, Sarkar AK, Bachhawat BK. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I. Relative therapeutic efficacy of free and liposomal amphotericin-B. Indian Journal of Biochemistry and Biophysics 26: 351–356, 1989Google Scholar
  3. Allen TM, Hansen C, Rutledge J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochimica et Biophysica Acta 981: 27–35, 1989PubMedCrossRefGoogle Scholar
  4. Alving CR. Liposomes as drug carriers for treatment of leishmaniasis. In Yagi (Ed.) Medical application of liposomes, pp. 105–111, Japan Scientific Societies Press, Tokyo, 1986Google Scholar
  5. Bally MB, Nayar R, Masin D, Hope MJ, Cullis PR, et al. Liposomes with entrapped doxorubicin exhibit extended blood residence times. Biochimica et Biophysica Acta 1023: 133–139, 1990PubMedCrossRefGoogle Scholar
  6. Bard DR, Knight CG, Page-Thomas DP. Effect of intra-articular injection of lutetium-177 in chelator liposomes on the progress of an experimental arthritis in rabbits. Clinical and Experimental Rheumatology 3: 237–242, 1985PubMedGoogle Scholar
  7. Bonte F, Juliano RL. Interactions of liposomes with serum proteins. Chemistry and Biophysics of Lipids 40: 359–372, 1986CrossRefGoogle Scholar
  8. Bradfield JWB. The reticulo-endothelial system and blood clearance. In Davis et al. (Eds) Microspheres and drug therapy: pharmaceutical, immunological and medical aspects, pp. 25–37, Elsevier Science Publishers, Amsterdam, 1984Google Scholar
  9. Celio LA, DiGregorio GJ, Ruch E, Pace J, Piraino AJ. Doxorubicin and 5-fluorouracil plasma concentrations and detectability in parotid saliva. European Journal of Clinical Pharmacology 24: 261–266, 1983PubMedCrossRefGoogle Scholar
  10. Cho MJ, Scieszka JF, Cramer CT, Thompson DP, Vidmar TJ. Neutrophil-mediated transport of liposomes across Madin Darby canine kidney epithelial cell monolayer. Pharmaceutical Research 6: 78–84, 1989PubMedCrossRefGoogle Scholar
  11. Chow DD, Essien HE, Padki MM, Hwang KJ. Targeting small unilamellar liposomes to hepatic parenchymal cells by dose effect. Journal of Pharmacology and Experimental Therapeutics 248: 506–513, 1989PubMedGoogle Scholar
  12. Delgado G, Potkul RK, Treat JA, Lewandowski GS, Batrer JF, et al. A phase I/II study of intraperitoneally administered doxorubicin entrapped in cardiolipin liposomes in patients with ovarian cancer. American Journal of Obstetrics and Gynecology 160: 812–819, 1989PubMedGoogle Scholar
  13. Druckmann S, Gabizon A, Barenholz Y. Separation of liposomeassociated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. Biochimica et Biophysica Acta 980: 381–384, 1989PubMedCrossRefGoogle Scholar
  14. Ellens H, Mayhew E, Rustum YM. Reversible depression of the reticuloendothelial system by liposomes. Biochimica et Biophysica Acta 714: 479–485. 1982PubMedCrossRefGoogle Scholar
  15. Ellens H, Rustum Y, Mayhew E, Ledesma E. Distribution and metabolism of liposome-encapsulated and free 1-B-D-Arabinofuranosylcytosine (Ara-C) in dog and mouse tissues. Journal of Pharmacology and Experimental Therapeutics 222: 324–330, 1982PubMedGoogle Scholar
  16. Farr SJ, Kellaway IW, Palfry-Jones DR, Woolfrey SG. 99m-Technetium as a marker of liposomal deposition and clearance in the human lung. International Journal of Pharmaceutics 26: 303–316, 1985CrossRefGoogle Scholar
  17. Fielding RM, The use of inhaled liposome formulations for drug delivery to the lungs and systemic circulation. Proceedings of the Western Pharmacology Society 32: 103–106, 1989PubMedGoogle Scholar
  18. Fielding RM, Smith PC, Wang LH, Porter J, Guo LSS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation in rats. Antimicrobial Agents and Chemotherapy, in press, 1991Google Scholar
  19. Gabizon A, Price DC, Huberty RS, Braesalier RS, Papahadjopoulos D. Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodisposition and imaging studies. Cancer Research 50: 6371–6378, 1990PubMedGoogle Scholar
  20. Gabizon A, Sulkes A, Peretz T, Druckmann S, Goren D, et al. Liposome-associated doxorubicin: preclinical pharmacology and exploratory clinical phase. In Lopez-Berestein & Fidler (Eds) Liposomes in the therapy of infectious diseases and cancer, pp. 391–402, Alan R. Liss Inc., New York, 1989Google Scholar
  21. Grant LD, Kaesberg PR, Ershler WB. Immunologic effects of cancer chemotherapy. In Powis et al. (Eds) The toxicity of anti-cancer drugs, pp. 167–197, Pergamon Press, New York, 1991Google Scholar
  22. Gregoriadis G (Ed.) Liposome technology, vol. 1–3, CRC Press Inc., Boca Raton, 1984Google Scholar
  23. Gregoriadis G (Ed.) Liposomes as drug carriers, recent trends and progress, John Wiley & Sons Ltd, 1988Google Scholar
  24. Guo LSS, Radhakrishnan R, Redemann CT. Adhesion of positively charged liposomes to mucosal tissues. Journal of Liposome Research 1: 319–337, 1990CrossRefGoogle Scholar
  25. Heath TD, Brown CS. Liposome dependent delivery of N-(phosphonacetyl)-L-aspartic acid to cells in vitro. Journal of Liposome Research 1: 303–317, 1990CrossRefGoogle Scholar
  26. Hospenthal D, Gretzinger K, Rogers A. Treatment of a murine model of systemic candidiasis with liposomal amphotericin B bearing antibody to Candida albicans. Journal of Medical Microbiology 30: 193–197, 1989PubMedCrossRefGoogle Scholar
  27. Hunneyball IM. Intra-articular administration of drugs. Pharmacy International 118–122: May 1986Google Scholar
  28. Hunt CA, MacGregor RD, Siegel RA. Central role of pharmacokinetics in determining the feasibility of targeting drug delivery. In Welling (Ed.) Pharmacokinetics: regulatory industrial academic perspectives, pp. 285–306, Marcel Dekker, New York, 1988Google Scholar
  29. Hwang KJ. Liposome pharmacokinetics. In Ostro (Ed.) Liposomes: from biophysics to therapeutics, pp. 109–156, Marcel Dekker Inc., New York, 1987Google Scholar
  30. Hwang KJ, Padki MM, Chow DD, Essien HE, Lai JY, et al. Uptake of small liposomes by non-reticuloendothelial tissues. Biochimica et Biophysica Acta 901: 88–96, 1987PubMedCrossRefGoogle Scholar
  31. Juliano RL. Pharmacokinetics of liposome-encapsulated drugs. In Knight (Ed.) Liposomes: from physical structure to therapeutic applications, pp. 391–406, Elsevier/North Holland Biomedical Press, Amsterdam, 1981Google Scholar
  32. Kan V, Bennett J, Amantea M, Smolskis M, Grasela D. Comparative safety and pharmacokinetic study of amphotericin B lipid complex (ABLC) and amphotericin B desoxycholate (AB) in healthy young male volunteers. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 21–24, 1990. Abstract 4, p. 87, 1990Google Scholar
  33. Kellaway IW, Farr SJ. Liposomes as drug delivery systems to the lung. Advanced Drug Delivery Reviews 5: 149–161, 1990CrossRefGoogle Scholar
  34. Khoobehi B, Payman GA, McTurnan WG, Niesman MR, Magin RL. Externally triggered release of dye and drugs from liposomes into the eye. Ophthalmology 95: 950–955, 1988PubMedGoogle Scholar
  35. Kim S, Kim DJ, Geyer MA, Howell SB. Multivesicular liposomes containing 1-B-D-Arabinofuranosylcytosine for slow-release intrathecal therapy. Cancer Research 47: 3935–3937, 1987PubMedGoogle Scholar
  36. Kimelberg HK, Mayhew EG. Properties and biological effects of liposomes and their uses in pharmacology and toxicology. CRC Critcal Reviews in Toxicology 6: 25–79, 1978CrossRefGoogle Scholar
  37. Kirsh R, Poste G. Liposome-mediated drug delivery to mononuclear phagocytes in vivo: applications in antimicrobial therapy. In Yagi K (Ed.) Medical application of liposomes, pp. 99–104, Japan Scientific Societies Press, Tokyo, 1986Google Scholar
  38. Lasic DD. The mechanism of vesicle formation. Biochemical Journal 256: 1–11, 1988PubMedGoogle Scholar
  39. Lee VHL, Urrea PT, Smith RE, Schanzlin DJ. Ocular drug bioavailability from topically applied liposomes. Survey of Ophthalmology 29: 335–348, 1985PubMedCrossRefGoogle Scholar
  40. Levy G. Targeted drug delivery — some pharmacokinetic considerations. Pharmaceutical Research 4: 3–4, 1987PubMedCrossRefGoogle Scholar
  41. Lichtenberg D, Barenholz Y. Liposomes: preparation, characterization and preservation. In Glick (Ed.) Methods of biochemical analysis, Vol. 33, pp. 337–461, John Wiley & Sons, New York, 1988CrossRefGoogle Scholar
  42. Lidgate DM, Feigner PL, Fleitman JS, Whatley J, Fu RC-C. In vitro and in vivo studies evaluating a liposome system for drug solubilization. Pharmaceutical Research 5: 759–764, 1988PubMedCrossRefGoogle Scholar
  43. Lopez-Berestein G, Fidler I (Eds). Liposomes in the therapy of infectious diseases and cancer, Alan R, Liss, Inc., New York, 1989Google Scholar
  44. Machy P, Leserman L. Liposomes in cell biology and pharmacology, John Libbey & Company Ltd, London, 1987Google Scholar
  45. Martin FJ. Pharmaceutical manufacturing of liposomes. In Tyle (Ed.) Specialized drug delivery systems, pp. 267–316, Marcel Dekker Inc., New York, 1990Google Scholar
  46. Morgan JR, Williams LA, Howard CB. Technetium-labelled liposome imaging for deep-seated infection. British Journal of Radiology 58: 35–39, 1985PubMedCrossRefGoogle Scholar
  47. Mufson D, Guo LSS, Fielding RM. Amphotericin B-cholesteryl sulfate complex (ABCD): stability and tissue distribution of a novel dosage form. Proceedings of the International Symposium on the Controlled Release of Bioactive Materials 17: 81–82, 1990Google Scholar
  48. Nashat KH, Slater DN, Underwood JCE, Triger DR, Woods HF. Phagocytic function in the isolated perfused rat liver, an experimental model. Journal of Hepatology 1: 153–166, 1985PubMedCrossRefGoogle Scholar
  49. Osborne MP, Richardson VJ, Jeyasingh K, Ryman BE. Radionuclide-labelled liposomes: a new lymph node imaging agent. International Journal of Nuclear Medicine in Biology 6: 75–83, 1979CrossRefGoogle Scholar
  50. Papahadjopoulos D (Ed.) Liposomes and their uses in biology and medicine. Annals of the New York Academy of Sciences 308: 1–462, 1978Google Scholar
  51. Patterson TF, Andriole VT. The role of liposomal amphotericin B in the treatment of systemic fungal infections. European Journal of Cancer and Clinical Oncology 25 (Suppl. 2): S63–S68, 1990Google Scholar
  52. Popescu MC, Swenson CE, Ginsberg RS. Liposome-mediated treatment of viral, bacterial and protozoal infections. In Ostro (Ed.) Liposomes: from biophysics to therapeutics, pp. 219–251, Marcel Dekker Inc., New York, 1987Google Scholar
  53. Powis G. Toxicity of free radical forming anticancer agents. In Powis et al. (Eds) The toxicity of anticancer drugs, pp. 106–151, Pergamon Press, New York, 1991Google Scholar
  54. Presant CA, Proffitt RT, Turner AF, Williams LE, Winsor D, et al. Successful imaging of human cancer with Indium-111-labeled phospholipid vesicles. Cancer 62: 905–911, 1988PubMedCrossRefGoogle Scholar
  55. Raab W. Liposomen — eine neue Form dermatologischer Wirkstofftrager. Artzliche Kosmetologie 18: 213–224, 1988Google Scholar
  56. Ranade VV. Drug delivery systems: 1 Site-specific drug delivery using liposomes as carriers. Journal of Clinical Pharmacology 29: 685–694, 1989PubMedGoogle Scholar
  57. Riaz M, Weiner N, Martin F. Liposomes. In Lieberman et al. (Eds) Pharmaceutical dosage forms: disperse systems, vol. 2, pp. 567–603, Marcel Dekker Inc., New York, 1988Google Scholar
  58. Roerdink FH, Regts J, Van Leeuwen B, Scherphof G. Intrahepatic uptake and processing of intravenously injected small unilamellar phospholipid vesicles in rats. Biochimica et Biophysica Acta 770: 195–202, 1984PubMedCrossRefGoogle Scholar
  59. Saba TM. Physiology and physiopathology of the reticuloendothelial system. Archives of Internal Medicine 126: 1031–1052, 1970PubMedCrossRefGoogle Scholar
  60. Sanders SW, Buchi KN, Goddard MS, Lang J, Tolman KG. Pharmacokinetics and tolerance of cholesterol sulfate complex of amphotericin B (ABCD) administered to healthy volunteers. Antimicrobial Agents and Chemotherapy, in press, 1991Google Scholar
  61. Schäfer-Korting M, Korting HC, Braun-Falco O. Liposome preparations: a step forward in topical drug therapy for skin disease. Journal of the American Academy of Dermatology 21: 1271–1275, 1989PubMedCrossRefGoogle Scholar
  62. Scherphof GL, Spanjer HH, Dijkstra J, Derksen JTP, Roerdink FH. Participation of Kupffer cells and hepatocytes in hepatic uptake and processing of liposomes. In Yagi (Ed.) Medical application of liposomes, pp. 43–54, Japan Scientific Societies Press, Tokyo, 1986Google Scholar
  63. Schumann G, van Hoogevest P, Fankhauser P, Probst A, Peil A, et al. Comparison of free and liposomal MTP-PE: pharmacological, toxicological and pharmacokinetic aspects. In Lopez-Berestein & Fidler (Eds) Liposomes in the therapy of infectious diseases and cancer, Alan R. Liss, Inc., New York, 1989Google Scholar
  64. Sculier J-P, Brassine C, Laduron C, Delcroix C, Hollaert C, et al. Phase 1 study, with pharmacokinetic analysis, of intravenous administration of 6-aminochrysene entrapped in sonicated liposomes in patients with advanced cancer. Journal of Liposome Research 1: 177–193, 1989CrossRefGoogle Scholar
  65. Sculier JP, Coune A, Meunier F, Brassinne C, Laduron C. Pilot study of amphotericin B entrapped in sonicated liposomes in cancer patients with fungal infections. European Journal of Cancer and Clinical Oncology 24: 527–538, 1988CrossRefGoogle Scholar
  66. Senior JH. Fate and behavior of liposomes in vivo: a review of controlling factors. Critical Reviews in Therapeutic Drug Carrier Systems 3: 123–193, 1987PubMedGoogle Scholar
  67. Smits JFM, Thyssen HHW. Spatial control of drug action: theoretical considerations on the pharmacokinetics of target-aimed drug delivery. In Struyker-Boudier (Ed.) Rate-controlled drug administration and action, pp. 83–114, CRC Press, Boca Raton, 1986Google Scholar
  68. Speth PAJ, Raijmakers RAP, Boezeman JBM, Linssen PCM, deWitte TJM, et al. In vivo cellular adriamycin concentrations related to growth inhibition of normal and leukemic human bone marrow cells. European Journal of Cancer and Clinical Oncology 24: 667–674, 1988CrossRefGoogle Scholar
  69. Stirk AH, Baldeschwieler JD. Mechanism of endocytosis of surface-modified liposomes by mouse peritoneal macrophages. In Yagi (Ed.) Medical application of liposomes, pp. 31–41, Japan Scientific Societies Press, Tokyo, 1986Google Scholar
  70. Sunamoto J. Applications of polysaccharide-coated liposomes in chemotherapy and immunotherapy. In Yagi (Ed.) Medical application of liposomes, pp. 121–129, Japanese Scientific Societies Press, Tokyo, 1986Google Scholar
  71. Svensson CK, Woodruff MN, Lalka D. Influence of protein binding and use of unbound (free) drug concentrations. In Evans, et al. (Eds) Applied pharmacokinetics: principles of therapeutic drug monitoring, 2nd ed., pp. 187–219, Applied Therapeutics Inc., Spokane, 1986Google Scholar
  72. Szoka F, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annual Review of Biophysics and Bioengineering 9: 467–508, 1980PubMedCrossRefGoogle Scholar
  73. Taylor KMG, Taylor G, Kellaway IW, Stevens J. The influence of liposomal encapsulation of sodium cromoglycate pharmacokinetics in man. Pharmaceutical Research 6: 633–636, 1989PubMedCrossRefGoogle Scholar
  74. Thies RL, Cowens DW, Cullis PR, Bally MB, Mayer LD. Method for rapid separation of liposome-associated doxorubicin from free doxorubicin in plasma. Analytical Biochemistry 188: 65–71, 1990PubMedCrossRefGoogle Scholar
  75. Tollemar J, Ringden O, Tyden G. Liposomal amphotericin-B (AmBisome) treatment in solid organ and bone marrow transplant recipients: efficacy and safety evaluation. Clinical Transplantation 4: 167–175, 1990Google Scholar
  76. Van Rooijen N. The liposome-mediated macrophage, ‘suicide’ technique. Journal of Immunological Methods 124: 1–6, 1989PubMedCrossRefGoogle Scholar
  77. Wasan KM, Vadiei K, Lopez-Berestein G, Luke DR. Pharmacokinetics, tissue distribution, and toxicity of free and liposomal amphotericin B in diabetic rats. Journal of Infectious Diseases 161: 562–566, 1990PubMedCrossRefGoogle Scholar
  78. Weiner N, Chiang C-M. Gastrointestinal uptake of liposomes. In Gregoriadis (Ed.) Liposomes as drug carriers, recent trends and progress, pp. 599–607, John Wiley & Sons Ltd, 1988Google Scholar
  79. Woodle MC, Papahadjopoulos D. Liposome preparation and size characterization. Methods in Enzymology 171: 193–217, 1989PubMedCrossRefGoogle Scholar
  80. Zumbuhl O, Waldvogel S, Asanger M, Roos K, Velvart M, et al. Liposomes as drug delivery systems. In Muller (Ed.) Controlled drug delivery. Wissenschaftliche Verlagsgesellschaft, Stuttgart, 1987Google Scholar

Copyright information

© Adis International Limited 1991

Authors and Affiliations

  • Robert M. Fielding
    • 1
  1. 1.Pharmacology/Toxicology GroupLiposome Technology, Inc.Menlo ParkUSA

Personalised recommendations